Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems

Cancer Research

Volumn 56, Issue 3, 1996, Pages 556-562

  Perego, Paola ^a   Giarola, Monica ^a   Righetti, Sabina C ^a   Supino, Rosanna ^a   Caserini, Claudia ^a   Delia, Domenico ^a   Pierotti, Marco A ^a   Miyashita, Toshiyuki ^b   Reed, John C ^b   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; MELPHALAN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IONIZING RADIATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENES, P53; GENES, REPORTER; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 8944263468     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Andrews, P A , and Howell, S B Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990
2. Scanlon, K. J., Kashani-Sabet, M , Tone, T., and Funato, T. Cisplatin resistance in human cancers. Pharmacol. Ther., 52: 385-406, 1991.
3. Hamilton, T C , O'Dwyer, P. J., and Ozols, R F. Platinum analogues in preclinical and clinical development. Curr. Opin. Oncol , 5: 1010-1016, 1993.
4. Gately, D P , and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin a review Br J Cancer, 67: 1171-1176, 1993
5. Loh, S. Y , Mistry, P , Kelland, L R., Abel, G., Murrer, B. A., and Harrap, K R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum(II) and (IV) ammine/amine complexes. Br. J. Cancer, 66: 1109-1115, 1992
6. Mistry, P , Kelland, L R., Abel, G., Sidhar, S., and Harrap, K. R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64: 215-220, 1991.
7. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2: 275-280, 1990.
8. Ormerod, M. G., Orr, R. M., and Peacock, J. H The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br. J. Cancer. 69: 93-100, 1994.
9. Nelson, W. G., and Kastan, M B. DNA strand breaks: the DNA template alterations that trigger p53-depeadem DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
10. Oren, M. Relationship of p53 to the control of apoptotic cell death. Cancer Biol., 5: 221-227, 1994.
11. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nature Genet., 4: 42-46, 1993.
12. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
13. Miyashita, T., and Reed, J C. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell, 80: 293-299, 1995.
14. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol , 124: 1-6, 1994.
15. Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise, L. H , Thompson, C. B., Golemis, E., Fong, L , Wang, H-G., and Reed, J. C. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA, 91: 9238-9242, 1994.
16. Oltvai, Z. N., Milliman, C. L , and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
17. Kohn, K. W., Ewing, R. A., Erickson, L. C., and Zwelling, L. Measurement of strand breaks and cross-links by alkaline elution. In: E. C Freidberg and P. C. Hanawalt (eds.), DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker, 1981.
18. Donghi, R., Longoni, A., Pilotti, S., Michieli, P , Della Porta, G., and Pierotti, M A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest., 91. 1753-1760, 1993.
19. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
20. Walker, L. J., Craig, R. B., Harris, A. L., and Hickson, D. A role for the human DNA repair enzyme HAPI in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res., 22: 4884-4889, 1994.
21. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and box gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
22. Segal, G. M., Smith, T. D., Heinrich, M. C., Ey, F. S., and Bagby, G. C. Jr. Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides. Blood, 80: 609-616, 1992
23. Unger, T., Nau, M. M., Segal, S., and Minna, J. D Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation transdominant inhibition, and transformation suppression. EMBO J., 11: 1383-1390, 1992.
24. Miyashita, T , Harigai, M., Hanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131-3135, 1994.
25. Phahl, M., Tzukerman, M., Zhang, X., Lehmann, J., Hermann, T., Wills, K. N., and Graupne, G. Nuclear retinoic acid receptors: cloning, analysis, and function Methods Enzymol., 189: 256-270, 1990.
26. Greenblatt, M. S , Bennett, W. P., Hollstein, M., and Harris, C. C Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
27. Blondal, J. A., and Benchimol, S. The role of p53 in tumor progression. Semin. Cancer Biol , 5: 177-186, 1994.
28. Zambetti, G. P., Bargonetti, J., and Walker. J Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes & Dev., 6: 1143-1152, 1992.
29. Brown, R. p53: a target for new anticancer drugs or a target for old drugs? Ann. Oncol., 4: 623-629, 1993.
30. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad Sci. USA, 89. 4495-4499, 1992.
31. Brown, R., Clugston, C , Burns, P., Edlin, A., Vasey, P., Vojtesek, B., Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int. J Cancer, 55: 678-684, 1993.
32. Biard, D S. F , Martin, M., Le Rhum, Y., Duthu, A., Lefaix, J L., May, E., and May, P. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res., 54: 3361-3364, 1994
33. Fan, S , El-Deiry, W S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J , Magrath, I., Kohn, K. W , and O'Connor, M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
34. Lowe, S. W., Bodis, S , McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo Science (Washington DC), 266: 807-810, 1994.
35. Vogelstein, B., and Kinzler, K. W. X-rays strike p53 again. Nature (Lond), 370 174-175, 1994.
36. Bartek, J., Iggo, R., and Lane, D P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899, 1990.
37. Stephen, C. W., and Lane, D. P. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J. Mol Biol., 225: 577-583, 1992
38. 1 arrest and apoptosis Cancer Res , 54: 1169-1174, 1994.
39. Zhan, Q., Fan, S., Bae, I , Guillouf, C., Liebermann, D. A., O'Connor P. M , and Fornace, A J. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9, 3743-3751, 1994.
40. Miyashita, T , Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B , and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo Oncogene, 9: 1799-1805, 1994